Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo Unloads Lucozade, Ribena Nutritional Beverages

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline’s latest consumer business divestment, of Lucozade sports beverages and Ribena fruit drinks, reflects the company’s focus on pharmaceuticals and emerging markets, between which the beverage brands were somewhat lost.

You may also be interested in...



Advertising Regulation In Brief: NAD flags ad labeled “news”

NAD flags ad labeled “news”; ASA nixes Lucozade “better than water” claims; Oxford Biolabs fails to substantiate claims; Naked Juice trips on health claims rewrite; and Vitabotics substantiates Visionace claims.

Advertising Regulation In Brief: NAD flags ad labeled “news”

NAD flags ad labeled “news”; ASA nixes Lucozade “better than water” claims; Oxford Biolabs fails to substantiate claims; Naked Juice trips on health claims rewrite; and Vitabotics substantiates Visionace claims.

Sales & Earnings In Brief

Sanofi now world’s No. 3 OTC player; Glaxo weighs Lucozade energy drink divestment; NBTY wraps Balance Bar integration; Vicks launches in Europe boost Teva OTC business; flu trend breeds cautious optimism for Prestige Brands; USANA and Nu Skin face tough times for multilevel marketers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel